Search hospitals > Illinois > Canton
Illinois CancerCare-Canton
Claim this profileCanton, Illinois 61520
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
384 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Canton is a medical facility located in Canton, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Canton is involved with conducting 384 clinical trials across 474 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
239 reported clinical trials
297 drugs studied
James L. WadeDecatur Memorial Hospital4 years of reported clinical research
Studies Breast Cancer
Studies Bladder Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Canton
Lung Cancer
Breast Cancer
Prostate Cancer
Breast cancer
Bladder Cancer
Pancreatic Cancer
Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Esophageal cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Canton?
Illinois CancerCare-Canton is a medical facility located in Canton, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Canton is involved with conducting 384 clinical trials across 474 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Canton located?
**Illinois CancerCare - Canton Office**
- **Address:** 180 S. Main St, Suite 2E, Canton, IL 61520
- **Open Days:** Wednesdays and Thursdays
- **Attending Physician:** Dr. Paul A. S. Fishkin
Who should I call to ask about financial aid or insurance network?
Illinois CancerCare-Canton offers financial assistance and insurance guidance. Contact them at (309) 243-3000, (866) 662-6564, or via their website. Organizations like the Partnership for Prescription Assistance, Patient Advocate Foundation Co-Pay Relief Program, and Good Days provide co-pay relief for cancer treatments. Graham Health System and OSF Healthcare, including Illinois CancerCare, offer billing and financial assistance; contact Graham Health System at 309-649-6818 for hospital bills and 309-647-0201 for medical group bills.
What insurance does Illinois CancerCare-Canton accept?
Illinois CancerCare-Canton accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. They also accept Coventry/First Health/Personal Care, Humana (HMO, PPO, Choice POS, Choice Care Network), Multiplan, PHCS (PHCS, Savility PPO), and more. Patients are advised to confirm their physician's participation in their insurance plan and notify the office of any necessary pre-certification.
What awards or recognition has Illinois CancerCare-Canton received?
Illinois CancerCare-Canton, located in Canton, Illinois, is nationally recognized as a top community research center by the American Society of Clinical Oncology. It has earned awards for advancing new cancer treatments through clinical trials by the Alliance for Clinical Trials in Oncology. Additionally, it is certified by the Quality Oncology Practice Initiative (QOPI®) for meeting the highest standards in outpatient hematology-oncology practices.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.